Source:http://linkedlifedata.com/resource/lhgdn/association:4005
| Predicate | Object |
|---|---|
| lhgdn:found_in | |
| lhgdn:geneRifSource |
In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy.
|
| lhgdn:mesh_code |
D019337
|
| lhgdn:associationIdType | |
| lhgdn:umls_code |